Top 20 Startups that help to cure COVID-19 in USA
Dec 01, 2025
|
Like
15
1
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
2
Funding: $1.4B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
3
Funding: $908.6M
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
4
Funding: $622.5M
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
5
Funding: $553.5M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
6
Funding: $553.1M
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
7
Funding: $510.6M
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
8
Funding: $506.6M
Medable's platform helps to facilitate the clinical trial process. Its mission is to reduce clinical trial timelines by 50%.
Medable's platform helps to facilitate the clinical trial process. Its mission is to reduce clinical trial timelines by 50%.
9
Funding: $497M
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
10
Funding: $496M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
11
Funding: $435M
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
12
Funding: $403M
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
13
Funding: $400M
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
14
Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
15
Funding: $334.9M
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
16
Funding: $325M
EverlyWell is a digital health platform that provides at-home health tests and lab results.
EverlyWell is a digital health platform that provides at-home health tests and lab results.
17
Funding: $283.4M
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
18
Funding: $278.9M
Wearable biosensor technology for wireless hospital and remote patient monitoring
Wearable biosensor technology for wireless hospital and remote patient monitoring
20
Funding: $256M
Truepill provides an API-connected healthcare infrastructure designed to revolutionize the patient experience.
Truepill provides an API-connected healthcare infrastructure designed to revolutionize the patient experience.
